Search Results

375 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco products ...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 29

    Thermochemical and thermophysical mapping of burning superslim and kingsize cigarettes

    EHLERT S.(1,3); CUI H.(2); HEIDE J.(3); XIE F.(2); DENG N.(2); LIU C.(4); McADAM K.(4); WALTE A.(1); ZIMMERMANN R.(3)
    (1) Photonion GmbH, Schwerin, Germany; (2) Zhengzhou Tobacco Research Institute of CNTC, Zhengzhou, Henan, P.R. China; (3) University of Rostock, Dept. of Analytical Chemistry, Rostock, Germany; (4) British American Tobacco, R&D Centre, Southampton, U.K.
    After presenting and publishing the proof of principle of the in-situ thermochemical and thermophysical mapping inside a burning Super Slim (SS) cigarette, we now extended the study scope to other cigarette formats and smoking regimes [1]. A Chinese ...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 44

    Lung biomarkers of harm/effect for tobacco regulatory research: opportunities and challenges – a literature review

    MAKENA P.(1); EDMISTON J.(2); BEATTIE E.(3); MASON E.(4); McEWAN M.(5); PRASAD K.(5)
    (1) RAI Services Company, Winston-Salem, NC, U.S.A.; (2) Altria Client Services LLC, Richmond, VA, U.S.A.; (3) Cliantha Research Limited, Canada; (4) Imperial Brands PLC, Bristol, U.K.; (5) British American Tobacco (Investments) Limited, Southampton, U.K.
    Biomarkers of potential harm (BoPH) are indicators of biological perturbations in response to smoking, which may contribute to smoking-related disease. In this review, a project of the CORESTA Biomarkers Sub-Group, we critically assessed the available ...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 54

    Clinical biomarkers of compliance for use in potentially reduced-risk product switching studies

    McEWAN M.(1); GALE N.(1); HARDIE G.(1); SCHERER M.(2); PLUYM N.(2); EBAJEMITO J.K.(1); CAMACHO O.M.(1); GRIFFITHS A.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, Research and Development, Southampton, U.K.; (2) ABF GmbH, Planegg, Germany
    Preclinical assessments and clinical studies have shown significant reductions in toxicants in tobacco heating product (THP) aerosols compared to smoke from conventional cigarettes. Further studies to assess if these toxicant reductions translate to ...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 28

    The in vitro biological assessment of a tobacco heating product and comparison with cigarette smoke

    TAYLOR M.; BREHENY D.; ADAMSON J.; BOZHILOVA S.; JAUNKY T.; SANTOPIETRO S.; TERRY A.; THORNE D.; GACA M.
    British American Tobacco, Southampton, U.K.
    Cigarette smoking is a risk factor for many diseases including cardiovascular disease, lung disease, and cancer. Recently there has been an increase in the development and consumer acceptance of novel nicotine and tobacco products including tobacco ...
  6. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 29

    Reversibility of in vitro biological effects in cigarette smoke-exposed 3D lung tissues following switching to a tobacco heating product

    HASWELL L.E.; BREHENY D.; CORKE S.; JAUNKY T.; SANTOPIETRO S.; BAXTER S.; MINET E.; THORNE D.; GACA M.
    British American Tobacco, Southampton, U.K.
    Tobacco heated products (THPs) potentially offer a safer alternative to combustible cigarettes. Recent in vitro studies have shown reduced THP biological effects compared to 3R4F reference cigarette smoke. Existing in vitro data, however, has been ...
  7. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 30

    In vitro RNA-seq-based toxicogenomics assessment shows reduced biological effect of tobacco heating products when compared to cigarette smoke

    MEREDITH S.; HASWELL L.E.; CORKE S.; VERRASTRO I.; BAXTER A.; BANERJEE A.; ADAMSON J.; JUANKY T.; PROCTOR C.J.; MINET E.; GACA M.
    British American Tobacco, Southampton, U.K.
    The battery of regulatory tests used to evaluate the risk of novel tobacco products such as heated tobacco products (THPs) presents some limitations including a bias towards the apical endpoints tested, and limited information on the mode of action. This ...
  8. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 31

    Comparative in vitro toxicological evaluation of novel tobacco heating product

    THORNE D.; BREHENY D.; PROCTOR C.J.; GACA M.
    British American Tobacco, Southampton, U.K.
    In vitro studies have been widely used to support toxicological evaluations of chemicals and complex mixtures including cigarette smoke. More recently the same assays have been employed for comparative assessment of tobacco heating products (THP) against ...
  9. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 49

    The CORESTA in vitro test battery for combustible tobacco products: update from the 2004 Rationale and Strategy Report

    LEE K.M.(1); JORDAN K.G.(2); WIECZOREK R.(3); MOENNIKES O.(4); CLEMENTS J.(5); CROOKS I.(6); HASHIZUME T.(7); MILLER J.(8); WEBER E.(9); YOSHINO K.(7)
    (1) Altria Client Services, Richmond, VA, U.S.A.; (2) RAI Services Company, Winston-Salem, NC, U.S.A.; (3) Imperial Brands, Reemtsma Cigarettenfabriken GmbH, Hamburg, Germany; (4) PMI R&D, Philip Morris Products S.A., Neuchâtel, Switzerland; (5) Covance Laboratories Ltd, Harrogate, U.K.; (6) British American Tobacco (Investments) Ltd, R&D, Southampton, U.K.; (7) Japan Tobacco Inc., Yokohama, Kanagawa, Japan; (8) JT International SA, Geneva, Switzerland; (9) Ökolab, Vienna, Austria
    In 2004, the CORESTA In Vitro Toxicity Task Force issued a rationale and strategy report, commonly known as “the CORESTA in vitro test battery guideline”. The goals of this guideline were to: 1) develop the rationale and strategy for conducting in vitro ...
  10. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 53

    Nicotine kinetics and subjective effects of two tobacco heating products compared to cigarettes and a nicotine replacement therapy

    HARDIE G.; GALE N.; McEWAN M.; EBAJEMITO J.K.; MURPHY J.; PROCTOR C.J.
    British American Tobacco (Investments) Limited, Research and Development, Southampton, U.K.
    Recently, clinical studies have shown reductions in exposure to tobacco smoke toxicants when smokers of conventional cigarettes switch to a tobacco heating product (THP). Studies on nicotine pharmacokinetics (PK) and subjective effects of potentially ...